These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Astrocytoma AND Ki-67 AND Prognosis
149 results:

  • 1. [Clinicopathological and molecular characteristics of pediatric gliomas: analysis of 111 cases].
    Xu H; Niu HL; Wang FH; Xu XK; Wang W; Yuan L; Chen K; Gao Q; Li LP; Xia JQ; Guo ZM
    Zhonghua Bing Li Xue Za Zhi; 2024 Sep; 53(9):922-928. PubMed ID: 39231745
    [No Abstract]    [Full Text] [Related]  

  • 2. Combination chemotherapy via poloxamer 188 surface-modified PLGA nanoparticles that traverse the blood-brain-barrier in a glioblastoma model.
    Madani F; Morovvati H; Webster TJ; Najaf Asaadi S; Rezayat SM; Hadjighassem M; Khosravani M; Adabi M
    Sci Rep; 2024 Aug; 14(1):19516. PubMed ID: 39174603
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.
    Wang Y; Xing H; Guo X; Chen W; Wang Y; Liang T; Wang H; Li Y; Jin S; Shi Y; Liu D; Yang T; Xia Y; Li J; Wu J; Liu Q; Qu T; Guo S; Li H; Zhang K; Wang Y; Ma W
    Cancer Med; 2024 Jul; 13(13):e7369. PubMed ID: 38970209
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysis.
    Shi Y; Kang X; Ge Y; Cao Y; Li Y; Guo X; Chen W; Guo S; Wang Y; Liu D; Wang Y; Xing H; Xia Y; Li J; Wu J; Liang T; Wang H; Liu Q; Jin S; Qu T; Li H; Yang T; Zhang K; Feng F; Wang Y; You H; Ma W
    BMC Neurol; 2024 Jun; 24(1):202. PubMed ID: 38877400
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Ki67 Index Correlates with Tumoral Volumetry and 5-ALA Residual Fluorescence in Glioblastoma.
    Sprenger F; da Silva Junior EB; Ramina R; Cavalcanti MS; Martins SB; Cerqueira MA; Falcão AX; Corrêa de Almeida Teixeira B
    World Neurosurg; 2024 Sep; 189():e230-e237. PubMed ID: 38857868
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. DKK3 Expression in Glioblastoma: Correlations with Biomolecular Markers.
    Caffo M; Casili G; Caruso G; Barresi V; Campolo M; Paterniti I; Minutoli L; Ius T; Esposito E
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612910
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Utilizing the amide proton transfer technique to characterize diffuse gliomas based on the WHO 2021 classification of CNS tumors.
    Filimonova E; Pashkov A; Borisov N; Kalinovsky A; Rzaev J
    Neuroradiol J; 2024 Aug; 37(4):490-499. PubMed ID: 38548655
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    Xi S; Huang Q; Zeng J
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma.
    Peng Y; Ren Y; Huang B; Tang J; Jv Y; Mao Q; Liu Y; Lei Y; Zhang Y
    Sci Rep; 2023 Jun; 13(1):9970. PubMed ID: 37340065
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Characterization and clinical implications of different malignant transformation patterns in diffuse low-grade gliomas.
    Jiang H; Zhu Q; Wang X; Li M; Shen S; Yang C; Zhao X; Li M; Ma G; Zhao X; Chen X; Yang J; Lin S
    Cancer Sci; 2023 Sep; 114(9):3708-3718. PubMed ID: 37332121
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Low expression of ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
    Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
    J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prediction of ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
    Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
    Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.
    Martínez-Bosch N; Vilariño N; Alameda F; Mojal S; Arumí-Uria M; Carrato C; Aldecoa I; Ribalta T; Vidal N; Bellosillo B; Menéndez S; Del Barco S; Gallego O; Pineda E; López-Martos R; Hernández A; Mesia C; Esteve-Codina A; de la Iglesia N; Balañá C; Martínez-García M; Navarro P
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980184
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
    Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
    [No Abstract]    [Full Text] [Related]  

  • 15. Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
    Yu Z; Zhou Z; Xu M; Song K; Shen J; Zhu W; Wei L; Xu H
    Comput Math Methods Med; 2023; 2023():1553408. PubMed ID: 36756387
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. An integrative non-invasive malignant brain tumors classification and ki-67 labeling index prediction pipeline with radiomics approach.
    Zhang L; Liu X; Xu X; Liu W; Jia Y; Chen W; Fu X; Li Q; Sun X; Zhang Y; Shu S; Zhang X; Xiang R; Chen H; Sun P; Geng D; Yu Z; Liu J; Wang J
    Eur J Radiol; 2023 Jan; 158():110639. PubMed ID: 36463703
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Timing of radiotherapy in glioblastoma based on IMRT and STUPP chemo-radiation: may be no need to rush.
    Li S; Guo F; Wang X; Zeng J; Hong J
    Clin Transl Oncol; 2022 Nov; 24(11):2146-2154. PubMed ID: 35753023
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
    Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
    Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Monocentric evaluation of ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract] [Full Text] [Related]  

    [Next]

    of 8.